Autophagy and neurodegeneration

Add to your list(s) Download to your calendar using vCal

• Professor David Rubinsztein ( CIMR)
• Wednesday 27 November 2019, 10:30-11:30
• Department of Chemistry, Cambridge, Todd Hamied Room.

If you have a question about this talk, please contact Catherine Xu.

Intracellular protein aggregation is a feature of many late-onset neurodegenerative diseases, including Parkinson’s disease, tauopathies, and polyglutamine expansion diseases (like Huntington’s disease (HD)). Many of these mutant proteins, like that causing HD, cause disease via toxic gain-of-function mechanisms. Therefore, the factors regulating their clearance are crucial for understanding disease pathogenesis and for developing rational therapeutic strategies. We showed that the autophagy inducer, rapamycin, reduced the levels of mutant huntingtin and attenuated its toxicity in cells, and in Drosophila, zebrafish and mouse HD models. We have extended the range of intracellular proteinopathy substrates that are cleared by autophagy to other related neurodegenerative disease targets, like alpha-synuclein in Parkinson’s disease and tau in various dementias. While autophagy induction is protective in models of various neuro-degenerative diseases, many of these diseases are associated with compromised autophagy. I will discuss two of our studies describing how autophagy can be regulated. The first will consider how the amino acid leucine regulates autophagy via mTORC1. The second will describe our drug repurposing efforts to identify compounds already used in humans for other indications that may be suitable as autophagy inducers in the brain.

This talk is part of the Biophysical Seminars series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biophysical Seminar Series 2016/17
• Biophysical Seminars
• Department of Chemistry
• Department of Chemistry, Cambridge, Todd Hamied Room
• Featured lists
• School of Physical Sciences

Note that ex-directory lists are not shown.